BACKGROUND: Serum C-reactive protein (CRP) is a marker of acute inflammatory response and has been associated with health outcomes in some studies. Inflammation and immune response may have potential prognostic implications for breast cancer survivors. METHODS: The Women's Healthy Eating and Living Study includes2,919 early-stage breast cancer survivors with serum collected 2 years postdiagnosis and follow-up for clinical outcomes over approximately 7 years. CRP concentrations were measured using high-sensitivity electrochemiluminescence assay. Outcomes, including all-cause mortality, breast cancer-specific mortality, and additional breast cancer events were oncologist verified from medical records and death certificates. Cox proportional hazards models were conducted with adjustment for potential confounding factors to generate HRs and 95% confidence intervals (CI). RESULTS:CRP concentrations in women diagnosed with breast cancer were associated with death due to any cause, death due to breast cancer, and additional breast cancer events, after adjustment for sociodemographic and cancer characteristics (lnCRP: P < 0.05 for all three outcomes). The HR for women with (vs. without) acute inflammation suggests a threshold effect on overall survival, rather than a dose-response relationship (≥ 10.0 mg/L vs. <1 mg/L: HR, 1.96; 95% CI, 1.22-3.13). Associations were similar for breast cancer-specific mortality (HR, 1.91; 95% CI, 1.13-3.23) and any additional breast cancer-related event (HR, 1.69; 95% CI, 1.17-2.43). CONCLUSIONS: Acute inflammation status (CRP ≥ 10 mg/L) may be an important independent biomarker for long-term survival in breast cancer survivors. IMPACT: Interventions to decrease circulating CRP concentrations in breast cancer survivors with acute inflammation may improve prognosis.
RCT Entities:
BACKGROUND: Serum C-reactive protein (CRP) is a marker of acute inflammatory response and has been associated with health outcomes in some studies. Inflammation and immune response may have potential prognostic implications for breast cancer survivors. METHODS: The Women's Healthy Eating and Living Study includes 2,919 early-stage breast cancer survivors with serum collected 2 years postdiagnosis and follow-up for clinical outcomes over approximately 7 years. CRP concentrations were measured using high-sensitivity electrochemiluminescence assay. Outcomes, including all-cause mortality, breast cancer-specific mortality, and additional breast cancer events were oncologist verified from medical records and death certificates. Cox proportional hazards models were conducted with adjustment for potential confounding factors to generate HRs and 95% confidence intervals (CI). RESULTS:CRP concentrations in women diagnosed with breast cancer were associated with death due to any cause, death due to breast cancer, and additional breast cancer events, after adjustment for sociodemographic and cancer characteristics (lnCRP: P < 0.05 for all three outcomes). The HR for women with (vs. without) acute inflammation suggests a threshold effect on overall survival, rather than a dose-response relationship (≥ 10.0 mg/L vs. <1 mg/L: HR, 1.96; 95% CI, 1.22-3.13). Associations were similar for breast cancer-specific mortality (HR, 1.91; 95% CI, 1.13-3.23) and any additional breast cancer-related event (HR, 1.69; 95% CI, 1.17-2.43). CONCLUSIONS:Acute inflammation status (CRP ≥ 10 mg/L) may be an important independent biomarker for long-term survival in breast cancer survivors. IMPACT: Interventions to decrease circulating CRP concentrations in breast cancer survivors with acute inflammation may improve prognosis.
Authors: Thomas A Pearson; George A Mensah; R Wayne Alexander; Jeffrey L Anderson; Richard O Cannon; Michael Criqui; Yazid Y Fadl; Stephen P Fortmann; Yuling Hong; Gary L Myers; Nader Rifai; Sidney C Smith; Kathryn Taubert; Russell P Tracy; Frank Vinicor Journal: Circulation Date: 2003-01-28 Impact factor: 29.690
Authors: Cynthia A Thomson; Anna Giuliano; Cheryl L Rock; Cheryl K Ritenbaugh; Shirley W Flatt; Susan Faerber; Vicky Newman; Bette Caan; Ellen Graver; Vern Hartz; Robin Whitacre; Felicia Parker; John P Pierce; James R Marshall Journal: Am J Epidemiol Date: 2003-04-15 Impact factor: 4.897
Authors: K V Albuquerque; M R Price; R A Badley; I Jonrup; D Pearson; R W Blamey; J F Robertson Journal: Eur J Surg Oncol Date: 1995-10 Impact factor: 4.424
Authors: Catherine R Marinac; Sandahl H Nelson; Shirley W Flatt; Loki Natarajan; John P Pierce; Ruth E Patterson Journal: Breast Cancer Res Treat Date: 2017-02-11 Impact factor: 4.872
Authors: Natalie C DuPré; Yujing J Heng; Benjamin A Raby; Kimberly Glass; Jaime E Hart; Jen-Hwa Chu; Catherine Askew; A Heather Eliassen; Susan E Hankinson; Peter Kraft; Francine Laden; Rulla M Tamimi Journal: Environ Res Date: 2020-04-15 Impact factor: 6.498
Authors: Avonne E Connor; Richard N Baumgartner; Kathy B Baumgartner; Christina M Pinkston; Stephanie D Boone; Esther M John; Gabriela Torres-Mejía; Lisa M Hines; Anna R Giuliano; Roger K Wolff; Martha L Slattery Journal: Mol Carcinog Date: 2014-10-22 Impact factor: 4.784
Authors: Keely A Muscatell; Naomi I Eisenberger; Janine M Dutcher; Steven W Cole; Julienne E Bower Journal: Brain Behav Immun Date: 2015-09-15 Impact factor: 7.217